Clinical Trial Update: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of eculizumab in patients with paroxysmal nocturnal hemoglobinuria has completed, with results posted detailing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Soliris (eculizumab) (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: COMPLETED | Results posted: 2018-03-13